VeChain now bridges 47 blockchains with zero service fees this month through Wanchain integration. BetterSwap pool gives above 20% APR, while Juicy Finance offers a stable 10% lending. VeChain’s DeFi ecosystem has expanded with Wanchain integration, allowing assets from 47 blockchains, including Bitcoin, Ethereum, and Solana, to be bridged onto VeChain. During October, bridge transactions [...]]]>VeChain now bridges 47 blockchains with zero service fees this month through Wanchain integration. BetterSwap pool gives above 20% APR, while Juicy Finance offers a stable 10% lending. VeChain’s DeFi ecosystem has expanded with Wanchain integration, allowing assets from 47 blockchains, including Bitcoin, Ethereum, and Solana, to be bridged onto VeChain. During October, bridge transactions [...]]]>

VeChain DeFi Guide: Earn BTC, ETH, and USDT with 20%+ APR Pools

  • VeChain now bridges 47 blockchains with zero service fees this month through Wanchain integration.
  • BetterSwap pool gives above 20% APR, while Juicy Finance offers a stable 10% lending.

VeChain’s DeFi ecosystem has expanded with Wanchain integration, allowing assets from 47 blockchains, including Bitcoin, Ethereum, and Solana, to be bridged onto VeChain.

During October, bridge transactions carry no service fees, with users only paying the gas fees on the origin chain. This lowers the cost of moving assets onto VeChain network for liquidity opportunities.

Participants will be rewarded for bridging assets through the “Bridge-to-Earn” campaign. Any qualifying transfer earns payouts in BTC, ETH, USDT, or B3TR, making liquidity support profitable even before deployment into yield pools.

Two High-Yield Pools Now Live

Right now, two protocols are live that give users different levels of income. BetterSwap’s B3TR-USDT liquidity pool is offering more than 20% APR. This pool pairs the B3TR sustainability token, already distributed to 1.7 million VeBetter users, with USDT, one of the most widely used stablecoins. On top of that, trading fees and farming rewards inside the ecosystem increase the total earnings.

BetterSwap runs a decentralized exchange protocol that connects VSwap, VExchange, and VRocket. This setup makes sure users always get the best prices inside the VeChain ecosystem. Liquidity providers benefit from activity across all trading routes instead of being confined to just one exchange.

For those seeking stability, Juicy Finance offers more than 10%  APR on USDT lending. The returns come from real borrowing demand in VeChain’s growing ecosystem. Lenders remain protected through over-collateralization measures and institutional-grade risk controls, which secure principal while generating steady returns.

Earn Dual Rewards with Zero Lockups

The Bridge-to-Earn program ensures participants gain immediate rewards for supporting liquidity. After that, they can choose to redeploy funds into yield protocols. There are no lock-up periods or staking requirements, giving participants direct control over their capital.

The model supports steady growth instead of short-term speculation. Rewards in BTC, ETH, USDT, and B3TR turn liquidity provision into a two-fold gain: one payout for bridging and another for yield farming or lending.

This approach builds long-term liquidity while ensuring participants do not enter at a loss. The campaign rewards stay active until the end of the current month, giving early entrants extra benefits.

Besides the two live pools, VeChain is finalizing development of a VET-USDT pool. This pair will increase liquidity for VeChain’s native token and give VET holders a direct way to earn profits. More pools with stablecoin options are also in progress.

The broader strategy aims to give users multiple channels to earn consistent returns while linking DeFi activities with VeChain’s sustainability programs. VeBetter’s user base feeds organic activity into trading volumes, which helps support long-term profits across the whole ecosystem.

VET is hovering near $0.02343, showing minimal movement today with an intraday range roughly between $0.02314 and $0.02385. Markets seem quiet, lacking strong directional momentum.

]]>
Market Opportunity
DeFi Logo
DeFi Price(DEFI)
$0.000306
$0.000306$0.000306
-3.16%
USD
DeFi (DEFI) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26